摘要
目的了解腹腔镜可调节性胃束带术（1aparoscopic adjustable gastric banding，LAGB）治疗病态肥胖症及伴发病的近期疗效。方法2006年10月至2007年12月，对50例病态肥胖症患者（其中伴发2型糖尿病11例、高血压3例、血脂异常15例、脂肪肝28例、睡眠呼吸暂停综合征1例和胆囊结石2例）行LAGB治疗，术后随访6-18个月，平均11．2个月，观察减重效果、伴发病变化及并发症发生情况。结果术后9个月、12个月和18个月平均体质量指数由术前（39±6）ks／m^2分别降至（31±4）ks／m^2、（28±7）kg／m^2和（27±7）kg／m^2（P〈0．05）；术后平均超重体重减重百分比分别为30％±11％、42％±13％和45％±13％；术后12个月和18个月超重体重减重百分比〉50％的人数分别达到20％和44％，66％-100％的患者术后12个月和18个月其肥胖相关伴发疾病得到完全缓解或好转。术后发生并发症4例，其中3例经保守治疗、1例经再次手术治疗痊愈。结论LAGB是一种安全、有效和可行的治疗肥胖症及其相关伴发疾病的方法。
Objective To evaluate the effect of laparoscopic adjustable gastric banding （LAGB） in patients with obesity and obesity-related comorbidities. Methods From Oct. 2006 to Dec. 2007, 50 morbidly obese patients including 11 cases with type 2 diabetes, 3 with hypertension, 15 with hyperlipidemia, 28 with fatty liver, 1 with obstructive sleep-apnea syndrome and 2 cases with gallstones underwent LAGB. The mean follow-up period for these patients was 11.2 months, ranging from 6 to 18 months. The weight loss, obesity-related comorbidities, outcomes and complications were evaluated. Results Mean BMI decreased significantly from preoperative （39 ±6）kg/m2 to postoperative （31 ± 4）kg/m2, （28 ±7）kg/m2 and （27 ±7）kg/m2 respectively at 9, 12 and 18 months （P 〈0. 05）. The mean excess weight loss at 9, 12 and 18 months postoperatively was 30% ± 11% ,42% ± 13% and 45% ±13% respectively. At 12 and 18 months, respectively, 20% and 44% of patients had 〉 50% excess weight loss. The obesity-related comorbidities resolved or improved in 66% - 100% of the patients at 12 and 18 months postoperatively. Complications occurred in 4 cases, among them 3 cases were cured conservatively and in 1 case reoperation was performed. Conclusions Based on short-term follow-up results, LAGB is a safe, effective and feasible technique in the treatment of patients with morbid obesity and obesity-related comorbidities.
出处
《中华普通外科杂志》
CSCD
北大核心
2009年第4期313-316,共4页
Chinese Journal of General Surgery
关键词
肥胖症
病态
腹腔镜检查
外科手术
Obesity, morbid
Laparoscopy
Surgical procedures, operative
